Pharmaceutical company specializing in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) announced having inked a partnership deal with Clinlogix, to support the clinical development of Psilocybin-for-Neuropsychiatric Disorders program being conducted by Tryp.
Clinlogix is a global Contact Research Organization (CRO) and Consulting Organization working to improve human quality of life by supporting innovations in life sciences and medical devices. The organization has its headquarters in Lower Gwynedd, Pennsylvania.
According to the partnership agreement, the two parties will join hands in a number of things including trial monitoring, bio-statistical analysis, data management and medical writing.
Founder and Chief Executive Officer of Clinlogix JeanMarie Markham Markham, says jointly with Tyrp they share a common goal to come up with innovations for unmet medical needs.
“Clinlogix is pleased to partner with Tryp Therapeutics in support of their next stage in clinical development. We look forward to leveraging our core expertise in clinical research to advance this novel technology. Sharing a common goal to deliver innovative solutions for unmet medical needs, Clinlogix is proud to support Tryp in advancing their novel treatments through the clinical trial process. We look forward to a collaborative and successful partnership,” said the CEO.